ORLANDO, Fla., July 25, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- Immune Therapeutics, Inc. (OTCQB:IMUN) ("Immune" “IMUN” or the "Company"), a clinical late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, is pleased to announce the publication of a peer reviewed scientific paper describing LDN as a promising treatment in immune related disease and cancer therapies as identified in the lab by Dr. Fengping Shan, IMUN’s Chief Scientific Officer.
The scientific paper by Fengping and Griffin et al. entitled, Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapies was recently published in the online edition of the International Immunopharmacology ( https://www.ncbi.nlm.nih.gov/pubmed/29885638)
In this paper, the authors describe and analyze naltrexone, a non-selective antagonist of opioid receptors, is mainly used as rehabilitation therapy for discharged opiate addicts to eliminate addiction in order to maintain a normal life and prevent or reduce relapse. In recent years, there have been some novel and significant findings on the off-label usage of naltrexone. Within a specific dosage window, LDN can act as an immunomodulator in multiple autoimmune diseases and malignant tumors as well as alleviate the symptoms of some mental disorders.
The results of increasing studies indicate that LDN exerts its immunoregulatory activity by binding to opioid receptors in or on immune cells and tumor cells. These new discoveries indicate that LDN may become a promising immunomodulatory agent in the therapy for cancer and many immune-related diseases. In this article, we review the pharmacological functions and mechanisms of LDN as well as its clinical therapeutic potential as revealed by our team and other researchers.
Until now, no review specific focused on the immunoregulatory functions of LDN has been reported. In this article, we provide a comprehensive summary of the immune-related pharmacological functions and potential mechanisms of LDN.
To our knowledge, LDN could modulate the immune system function of the body to resist an abnormal immune response, and it has been widely accepted by patients with MS, IBD such as CD and many types of malignant tumors. Successful reports of patients with fibromyalgia, ALS and type 1 diabetes treated with LDN are increasing. Future studies and clinical work are warranted to confirm the role of LDN in the treatment of immune-related diseases.
LDN may be considered as a novel immunomodulator and tumor biotherapy agent, which is routinely recommended for people with autoimmune diseases and cancer. At the same time, researchers also found that LDN could control appetite and the intake of high-sugar and high-fat foods and that the effect and mechanism of LDN on body weight control were of great value. Moreover, it is believed that LDN will have more novel dosage forms, such as passive transdermal delivery, liquid nasal spray and sustained-release preparations , in the near future.
Although there are many advantages of LDN therapy, such as low cost, low adverse reaction, high safety, easy availability and better compliance, some issues are still worth noting. Since LDN is thought to play a role in the regulation of inflammatory mediators and the upregulation of endogenous opioid receptors, physicians should be alert to patients who have prior chronic use of LDN in pain management when using exogenous opioids in order to prevent hypersensitivity to exogenous opioids.
Additionally, patient-funded research on LDN for the treatment of multiple sclerosis is good news for both doctors and patients, but attention should be paid to issues such as program reviews and conflicts of interest.
Noreen Griffith is currently attending the 22nd International AIDS Conference (AIDS 2018), taking place in Amsterdam, this week (July 23-27).
As well, as a testament to the work being done, Ms. Griffin has been invited to attend the SCON Summit on HIV and AIDS.
ABOUT IMMUNE THERAPEUTICS, INC.
Immune Therapeutics Inc. is a late stage clinical stage biopharmaceutical company focused on the development and commercialization of our highly innovative immunotherapies. IMUN is a biotechnology company developing T-Activation immunotherapies to achieve immunomodulation in patients with autoimmune and inflammatory disease and cancer and infectious diseases.
Stimulating the body’s immune system remains one of the most promising approaches in the treatment of Cancers, HIV, Autoimmune Diseases, inflammatory conditions and other chronic infectious diseases.
Forward-Looking Statements
This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company’s filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.
888-613-8802
http://www.immunetherapeutics.com/